Scilex(NASDAQ) SCLX

Market Cap$47.99M

Since IPO (2021)-97%

5 Year-97%

1 Year-49%

1 Month-26%

$5.64

-0.18%

-0.01Today

After hours$5.69+$0.05 (+0.89%)

Scilex last closing stock price
Metric	Price	Date
Last close	USD 5.65	2026-08-19

Scilex stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-18.12%	USD 6.90	2026-08-12
1 month	-26.05%	USD 7.64	2026-07-20
3 month	+53.28%	USD 3.69	2026-05-21
Year to date	-25.62%	USD 7.60	2025-12-31
1 year	-49.48%	USD 11.18	2025-08-19
3 year	-92.7%	USD 77.36	2023-08-18
5 year	-97.4%	USD 217.05	2021-08-20
Since inception	-97.37%	USD 214.66	2021-03-05

Scilex Financials at a Glance

Market Cap

$47.99M

Revenue (TTM)

$31.61M

Net Income (TTM)

-$448.35M

EPS (TTM)

-$49.80

P/E Ratio

-0.11

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$5.64

Volume

29,701.883

Open

$5.65

Price

$5.64

Volume

29,701.883

Open

$5.65

Previous Close

$5.80

Daily Range

$5.47 - $5.80

52-Week Range

$2.62 - $21.34

Estimated Earnings Date

Dec 2, 2026

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$5.64

Volume

29,701.883

Open

$5.65

Previous Close

$5.80

Daily Range

$5.47 - $5.80

52-Week Range

$2.62 - $21.34

Estimated Earnings Date

Dec 2, 2026

SCLX News

a scientist uses a pipette to work with medical samples.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scilex

Scilex develops medicines for people with pain, focusing on non-opioid options. Its products help those with nerve pain, migraines, and gout. These treatments aim to reduce pain without the risks linked to opioid drugs.

Pain Relief, Unpacked: What Scilex Sells

ZTlido (lidocaine patch): Prescription patch for nerve pain after shingles; approximately 91.5% of Q2 2025 revenue; used by adults with post-herpetic neuralgia.
ELYXYB (celecoxib oral solution): Liquid medicine for migraine attacks; about 9% of Q2 2025 revenue; targets adults needing fast migraine relief.
GLOPERBA (colchicine oral solution): Liquid for preventing gout flares; negative revenue in Q2 2025 due to returns; for adults with gout.
SP-102 (SEMDEXA): Gel for back pain injections; not yet approved; targets people with sciatica.
SP-103 and SP-104: New pain and fibromyalgia treatments in clinical trials; not yet generating revenue.

Growth Spurts and Strategic Moves

Launched ELYXYB in the U.S. in April 2023 and received Health Canada approval for ELYXYB in January 2025.
Launched GLOPERBA in the U.S. in June 2024 after licensing from Romeg Therapeutics.
Expanded global rights for ZTlido, ELYXYB, and GLOPERBA through licensing deals in 2024-2025.
Formed joint venture Scilex Bio in 2025 to develop KDS2010 for obesity and brain diseases.
Secured $100 million equity line with Tumim Stone Capital in July 2025 to support operations.

What Makes Scilex Stand Out

Scilex focuses on non-opioid pain relief, aiming to fill gaps in pain management. Its dedicated sales team targets key U.S. prescribers, supporting product reach. The company leverages licensing and partnerships to expand its portfolio and market access.

Five Things You Need to Know

Revenue was $10 million in Q2 2025, down 39.5% from Q2 2024.
Operating loss was $21 million in Q2 2025, 31.3% worse than Q2 2024.
Cash and equivalents were $4.1 million as of June 30, 2025.
Management reported substantial doubt about continuing as a going concern in 2025.

Bottom Line

Scilex has built a focused pain management portfolio and expanded through licensing and partnerships. The company faces financial challenges but continues to develop non-opioid therapies for pain.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Henry H. Ji, PhD

Website

www.scilexholding.com

Headquarters

Palo Alto, CA 94303, US

SCLX Financials

Key Financial Metrics (TTM)

Gross Margin

50.47%

Operating Margin

-903.52%

Net Income Margin

-1418.45%

Return on Equity

190.33%

Return on Capital

N/A

Return on Assets

-176.82%

Earnings Yield

-9.09%

Dividend Yield

0.00%

Payout Ratio

-0.12%

Stock Overview

Market Cap

$47.99M

Shares Outstanding

8.49M

Volume

29.70K

Avg. Volume

125.64K

Financials (TTM)

Gross Profit

$15.95M

Operating Income

-$285.59M

EBITDA

-$363.44M

Operating Cash Flow

-$17.49M

Capital Expenditure

-$427.07K

Free Cash Flow

-$17.92M

Cash & ST Invst.

$581.00K

Total Debt

$95.56M

Scilex Performance Analysis

Scilex annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 38,034,000	21.4%
2023	2023-12-31	USD 46,743,000	22.9%
2024	2024-12-31	USD 56,590,000	21.1%
2025	2025-12-31	USD 30,253,000	-46.5%

Scilex sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	6.7%
Q4	2025-12-31	-54.6%
Q1	2026-03-31	79.7%
Q2	2026-06-30	-11.3%

Scilex annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -6.09	-73.8%
2023	2023-12-31	USD -44.85	636.2%
2024	2024-12-31	USD -19.43	-56.7%
2025	2025-12-31	USD -36.48	87.7%

Scilex sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-198.8%
Q4	2025-12-31	86.5%
Q1	2026-03-31	-109.3%
Q2	2026-06-30	-165.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$7.64M

-22.8%

Gross Profit

$3.97M

-40.1%

Gross Margin

51.88%

N/A

Market Cap

$47.99M

N/A

Market Cap/Employee

$1.41M

N/A

Employees

N/A

Net Income

-$114.73M

-33.3%

EBITDA

-$29.42M

+27.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$581.00K

-85.8%

Total Debt

$95.56M

+128.8%

Accounts Receivable

$6.44M

-61.6%

Inventory

$4.17M

+65.6%

Long Term Debt

$12.51M

+1010.9%

Short Term Debt

$83.05M

+104.4%

Return on Assets

-1.77%

N/A

Return on Invested Capital

1.10%

N/A

Free Cash Flow

-$4.28M

-160.7%

Operating Cash Flow

-$6.74M

-195.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IXHLIncannex Healthcare Limited

IXHLIncannex Healthcare Limited$3.62+5.23%

CTORCitius Oncology, Inc.

CTORCitius Oncology, Inc.$0.76+0.88%

INOInovio Pharmaceuticals, Inc.

INOInovio Pharmaceuticals, Inc.$1.21-6.92%

VTGNVistaGen Therapeutics, Inc.

VTGNVistaGen Therapeutics, Inc.$0.24-1.23%

SEERSeer, Inc.

SEERSeer, Inc.$2.02-1.46%

LUCDLucid Diagnostics Inc.

LUCDLucid Diagnostics Inc.$0.96-4.91%

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$3.19+1.27%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$9.81+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$134.00-0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.88-0.03%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$41.20+0.06%

MRNAModerna

MRNAModerna$133.32-0.24%

NVDANvidia

NVDANvidia$216.85-0.00%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$17.55+0.11%

Questions About SCLX

What is the current price of Scilex?

Scilex is trading at $5.80 per share.

What is the 52-week range for Scilex?

Over the past 52 weeks, Scilex has traded between $2.62 and $21.34.

How much debt does Scilex have?

As of the most recent reporting period, Scilex reported total debt of $105.99M.

How much cash does Scilex have on hand?

Scilex reported $566.00K in cash and cash equivalents in its most recent financial results.

What is Scilex’s dividend yield?

Scilex does not currently have a dividend yield.

Scilex(NASDAQ) SCLX

Scilex Financials at a Glance

SCLX News

Why Shares of Scilex Are Up Monday

Why Shares of Scilex Are Dropping Monday

Why Shares of Scilex Slumped This Week

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Scilex

Pain Relief, Unpacked: What Scilex Sells

Growth Spurts and Strategic Moves

What Makes Scilex Stand Out

Five Things You Need to Know

Bottom Line

SCLX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Scilex Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SCLX

What is the current price of Scilex?

What is the 52-week range for Scilex?

How much debt does Scilex have?

How much cash does Scilex have on hand?

What is Scilex’s dividend yield?

Premium Investing Services